Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Triple Negative Breast Neoplasms × pyrotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 49 HER2-positive Breast Cancer 11 Carcinoma, Non-Small-Cell Lung 5 Brain Neoplasms 4 HER2 Positive Metastatic Breast Cancer 3 HER2 Positive Breast Cancer 3 Breast Diseases 3 Advanced Breast Cancer 3 Colorectal Neoplasms 2 Breast Cancer Invasive 2 Breast Cancer Female 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Solid Tumor 1 Salivary Gland Neoplasms 1 Rare Tumour 1 Rare Tumor 1 Pathologic Complete Response 1 Non-squamous NSCLC 1 Non Small Cell Lung 1 Neoplasm Metastasis 1 Metastatic Breast Cancer in the Brain 1 Lung Neoplasms 1 Locally Advanced Breast Cancer 1 HER2-positive Metastatic Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2-expressing Advanced Solid Tumors 1 HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane 1 HER2+ Early or Locally Advanced Breast Cancer 1 HER2+ Breast Cancer 1

Interventions

pembrolizumab 126 Carboplatin 109 Paclitaxel 94 Cyclophosphamide 72 Capecitabine 53 130-nm albumin-bound paclitaxel 52 Doxorubicin 41 Gemcitabine 38 Albumin-Bound Paclitaxel 33 atezolizumab 32 Taxes 32 Nivolumab 29 Docetaxel 28 Cisplatin 28 sacituzumab govitecan 25 Epirubicin 25 Bevacizumab 24 eribulin 23 olaparib 22 Specimen Handling 22 durvalumab 21 Magnetic Resonance Spectroscopy 20 camrelizumab 19 Biopsy 19 Drug Therapy 18 toripalimab 16 Everolimus 13 spartalizumab 12 liposomal doxorubicin 12 Radiotherapy 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03805399 2022-08-10

FUTURE

Fudan University

Phase 1/2 Unknown

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡